In Vitro Diagnostic
Summary
Table of Contents
This report analyzes the worldwide markets for Immunoassay Instruments in Millions of US$. The specific product segments analyzed are Enzyme Immunoassay Systems, Fluorescence Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay Systems. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual forecasts are provide...
More »Search ReportLinker
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Get this report today!
This report analyzes the worldwide markets for Immunoassay Instruments in Millions of US$. The specific product segments analyzed are Enzyme Immunoassay Systems, Fluorescence Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay Systems. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual forecasts are provided for each region and product segment for the period of 2000 through 2015. The report profiles 85 companies including many key and niche players worldwide such as Abbott Laboratories, Beckman Coulter, Biomerieux, Bio-Rad Laboratories Inc., Roche Diagnostics, Siemens Healthcare Diagnostics, and Ortho-Clinical Diagnostics. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
IMMUNOASSAY INSTRUMENTS MCP-3522
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Enzyme Immunoassay I-4
Fluorescence Immunoassay I-4
Chemiluminescence Immunoassay I-4
Radioimmunoassay I-4
Nephelometric Immunoassay I-4
II. EXECUTIVE SUMMARY
1. Industry Overview II-1
Outlook II-1
Market Promises Growth II-1
Industry Leading Players and Market Share II-1
Table 1: Leading Players in Worldwide Immunoassay Instruments
Market (2006-2007) - Percentage Breakdown by Value Sales for
Abbott, Siemens Healthcare Diagnostics, Bayer, Roche,
Biomerieux, Dade Behring, Diagnostic Products Corp,
Beckman-Coulter, Ortho Clinical Diagnostics, and Others
(includes corresponding graph/Chart) II-2
Table 2: Leading Diagnostics Companies Worldwide (2005) -
Diagnostics Sales for Roche, Abbott, Bayer, Becton Dickinson,
Beckman Coulter, Dade Behring, Ortho-Clinical Diagnostics,
and bioMerieux (includes corresponding Graph/Chart) II-3
Table 3: World Immunoassay Market by End-Use Industry (2004,
2005 & 2006): Percentage Breakdown by Value Sales for
Clinical, Food and Environment Industries (includes
corresponding Graph/Chart) II-3
Table 4: World Clinical Diagnostic Equipment Market by
Geographic Region (2005 & 2006): Percentage Breakdown by
Value Sales for US, Western Europe, Japan and Rest of World
(includes corresponding Graph/Chart) II-4
2. Industry Trends II-5
Instrument Rental - Name of the New Game II-5
Changing Scene for Immunodiagnostic Testing II-5
Hospital and Laboratory Consolidations Drive the Market for
Analytical Laboratory Equipment II-5
Immunoassays - the Second-Largest Group of In Vitro Diagnostic
Products II-5
Immunoassay Techniques for Testing Environmental Samples II-6
Application of Immunoassays for Trace Methodology II-6
Laboratory Automation on Rise II-6
Use of Immunoassays in Food Sciences and Quality Control II-7
Market for Adjunctive Therapies to Grow Fast II-7
Increasing Demand for Random Access Immunoanalyzers II-7
Advancement in Genetic Research Drives the Growth of this
Market Segment II-7
Introduction of Portable Immunoassay Systems Energizes the Market II-7
Technological Innovations Induces Growth II-8
Task-Targeted Automated Chemiluminescent Assays to Penetrate II-8
3. Immunoassays - Combine Chemistry and Immunology II-9
Definition and Description II-9
A Major Place in the Diagnostic Test Market II-9
Turning the Hour Glass Back II-10
Shift Towards Point-of-Care Test Systems II-10
Broad Application Range II-11
Labels - Necessary for Detection II-11
Customized Immunoassays II-11
Demerits of Immunoassays II-11
Radioimmunoassay II-12
Non-Isotopic Immunoassays II-12
4. Product Overview II-13
Components of Immunoassays II-13
Signal Response II-13
Labeled Tracer II-13
Binder II-13
Buffer Matrix II-13
Incubation Conditions II-13
Separation Process II-13
Standard Specimens II-14
Control Specimens II-14
Unknown Specimens II-14
Chemiluminescent Substrates - Growing Appeal II-14
Radioimmunoassay Analyzers, Gamma Counters II-14
Fundamentals of Operation II-15
Problems Involved II-16
Enzyme Immunoassay Analyzers, Fluorescence Immunoassay
Analyzers and Chemiluminescence’s Immunoassay Analyzers II-17
Enzyme Immunoassays II-17
Automation Enabled II-18
Customization of Assays II-18
ELISA - A Flexible Enzyme Immunoassay Test..... II-18
Constituents of ELISA II-19
Working II-19
Binding the Antigen and Antibody II-19
Conjugate Binding II-19
Evidence of Binding II-19
Fluorescence Immunoassay - Operating Principle II-19
Light Sources II-20
Sample Cell II-20
Filters II-20
Detector II-20
Time-Resolved Fluoroimmunoassay II-21
Chemiluminescence Immunoassay II-21
Types of Immunoassay Techniques II-21
Fluorescence Polarization Immunoassay II-21
Radiative Energy Attenuation (REA) II-22
Substrate-Labeled Fluorescence II-22
Enzyme Immunoassay with Fluorescence Detection II-22
Solid-Phase Microsphere Immunoassay II-23
Microparticle Enzyme Immunoassay (MEIA) II-23
Enzyme-Linked Fluorescence Immunoassay II-23
ELISA With Photometric Detection II-23
Dry-Phase Techniques II-24
Sandwich Technique II-24
Competitive Binding II-24
Reversible Complex Formation II-24
The Phase of Development II-25
Problems and Limitations.... II-25
Purchase Considerations II-26
Cost Considerations II-26
Nephelometric Immunoassay II-26
Nephelometry II-27
Types of Scatter II-27
Rayleigh Scatter II-27
Mie Scatter II-27
Rayleigh-Debye Scatter II-27
Key Components of Nephelometric Immunoassay Analyzers II-27
Light Sources II-27
Detectors II-28
Automated Nephelometers II-28
Modes of Operation II-29
Nephelometric Immunoassay Procedures II-29
Associated Problems II-29
Purchase Considerations II-30
Test Menu II-30
Analytical Range II-30
Linearity II-31
Specificity II-31
Precision II-31
Stability II-31
Carryover II-31
Downtime II-31
Upgrading / Interfacing II-31
Reagents II-31
Additional Features II-31
5. Technology Developments II-33
Rapid immunoassays for Diagnosis of Peptic Ulcers II-33
Latex Photometric Immunoassay Systems II-33
Gene Amplification Technology to Replace Immunoassays II-33
RAMP system from Response Biomedical II-33
Skye PharmaTech Develops S-100 Test II-33
Full Disease Profiling with Dade’s Dimension RxL Clinical
Chemistry System II-34
Bayer’s ADVIA - An Automation Platform II-34
Binax’s Rapid Flow-Thru Immunoassay System II-34
Abbott Launches LCx Technology Instrumentation II-34
6. End-Use Markets for Immunoassay Instruments II-35
Endocrine Testing Procedures II-35
Infectious Disease II-35
Blood Processing Market II-35
Cancer Testing Markets II-36
Drugs of Abuse Testing Market II-36
Therapeutic Drug Monitoring II-36
Immune Disease II-37
Blood Grouping and Typing. II-37
7. Technology Posing a Threat to Immunoassay II-38
Mature Technologies II-38
Cell Counting II-38
Clinical Chemistry II-38
Microbiology II-38
Emerging Technologies II-38
DNA Probes II-38
Miniaturization and Microchip Fabrication II-39
Blood Glucose Testing II-39
Immunohistochemistry (IHC) II-39
Non-Invasive Technology II-39
Image Analysis and Pattern Recognition II-39
Rapidly Growing Molecular Diagnostics II-40
New Technologies II-40
High-Definition Cell Assay Technologies II-40
(1) Rapid, High-Definition Assays for Cellular Efficacy (
RHACE) II-40
(2) Single-Cell Analysis of Physiological Effects (SAPhE) II-40
(3) Matrix Analysis of Genomically-Indexed Cells (MAGIC) II-40
8. In-Vitro Diagnostics - A Broad Discipline II-41
Definition of In Vitro Diagnostics II-41
Importance of IVD II-41
World IVD Market II-41
Table 5: World In-Vitro Diagnostics (IVD) Market by Product
Segment (2005): Percentage Breakdown of Value Sales for
Clinical Chemistry, Immunoassays, Microbiology & Virology,
Nucleic Acid, Histology & Cytology and Others (includes
corresponding Graph/Chart) II-42
Table 6: World In-Vitro Diagnostics Products Market by
Geographic Region (2005)- Percentage Breakdown by Values
Sales for US, Canada, Europe, Japan and Rest of World
(includes corresponding Graph/Chart) II-42
Factors Influencing IVD Industry: On A Scale of 1-5 II-42
Technologies Used in IVD II-43
Major End-Use Markets II-43
Table 7: World In-Vitro Diagnostic Products Market by End-Use
Segment (2005 & 2006E) - Percentage Breakdown by Value Sales
for Hospitals and Commercial Labs, Decentralized and
Ambulatory, and Patient Self-Testing (includes corresponding
Graph/Chart) II-43
Outlook II-43
Competition II-44
Table 8: Leading Players in the Worldwide In Vitro
Diagnostics (IVD) Market (2005) - Percentage Breakdown by
Value Sales for Roche Diagnostics, Abbott Laboratories,
Johnson & Johnson, Bayer Diagnostics, Beckman Coulter, Dade
Behring, and Others (includes corresponding Graph/Chart) II-44
9. A Review of Recent Past II-45
Bayer’s Acquisition of Chiron - The Turning Point II-45
10. Product Launches II-46
bioMérieux Introduces VIDAS® NT-proBNP II-46
Beckman Coulter Introduces UniCel DxC 880i Synchron® Access® II-46
Beckman Coulter Introduces UniCel® DxI 600 II-46
bioMérieux Introduces VIDAS® B·R·A·H·M·S PCT® Assay II-46
Siemens Rolls Out ADVIA Centaur® Cyclosporine (CsA) Assay II-46
Ortho-Clinical Diagnostics Launches VITROS Troponin I ES Assay II-46
Ortho-Clinical Diagnostics Introduces VITROS® Rubella IgG Assay II-47
Bayer Rolls Out ADVIA Centaur® XP System II-47
Bachem Releases Neuromedin S Immunoassays and Antibodies II-47
Roche Unveils The New Cobas 6000 Analyzer Series II-47
Ortho-Clinical Diagnostics Launches The VITROS NT-proBNP Assay II-47
Maxim Biotech Offers HIV-1 Urine EIA Kit II-47
Assay Designs Rolls Out The Correlate™ Small Molecule ELISA Kits II-48
Oxis and BioCheck Mull to Launch Immunoassay Products for
Oncology Research II-48
EDP Develops The CA1-18 EIA II-48
Instrumentation Laboratory’s Homocysteine Assay Gets FDA Nod II-48
Beckman Coulter Obtains FDA Clearance for Immunoassay System II-48
BioPAL to Develop Non-Invasive Diagnostic Assays II-48
Mobious Genomics Develops A New Prototype for Immunoassay II-49
Immunoassay Market Witnesses A Unique Fluoroimmunoassay II-49
Development of A Tissue-Culture-Based Enzyme-Immunoassay II-49
Development of An Immunoassay to Measure Progesterone II-49
The Freedom EVOlyzer II-49
Development of An Immunoassay to Detect HIV Type 1 Infections II-49
Idexx Tests Tecan’s BSE Antigen EIA Test Kit II-49
Bayer Introduces ADVIA Centaur® CP Immunoassay System II-50
Dade Behring Introduces N Latex CDT Assay in Europe II-50
DPC Launches Immunoassay Workcell II-50
Bayer Receives FDA Approval for Hepatitis B Assays II-50
Olympus Launches A New Immunoassay System II-50
LINCO Research Offers Multiple Immunoassays for Metabolic
Diseases II-50
Abbott Releases Automated Hepatitis C Virus Test for AxSYM®
System II-51
Technical Solutions Develops Binax's Rapid Flow-Thru
Immunoassay System II-51
EG&G Berthhold Introduces LB 953, an Automated Multi-Sample
Luminometer II-51
Bayer Diagnostics Develops an Automated Assay for Measuring
Oncoprotein HER-2/neu II-51
Sanofi Diagnostics Unveils Access Immunoassay System II-51
Bayer Receives FDA Approval for Anti-HBc-IgM assay II-52
Abbott Launches Second Automated Test For Hepatitis A Virus II-52
Bio-Rad Laboratories Launches The BioPlex™ 2200 II-52
Development of A microELISA System II-52
Development of A Dipstick Dye Immunoassay (DDIA) II-52
TOSOH Bioscience Offers AIA-360 Random Access Immunoassay
Analyzer (US) II-52
TOSOH Bioscience Unveils AIA®-1800 Automated Immunoassay
Analyzer (US) II-53
Beckman Introduces UniCel(tm) II-53
Molecular Devices Introduces Threshold® II-53
Diagnostic Introduces IMMULITE 1000 II-53
Diagnostic Products Introduces Chemiluminescent IMMULITE 2000
AlaTOP II-54
11. Recent Industry Activity II-55
Roche Acquires Ventana Medical Systems, Inc. II-55
Abbott Terminates Sale Agreement with GE II-55
Abbott Inks Agreement with Premier, Inc. II-55
Beckman Coulter Renews Agreement with MedAssets II-55
Beckman Coulter Extends Agreement Amerinet II-55
Beckman Coulter Extends Partnership with Bio-Rad II-56
Siemens Acquires Dade Behring II-56
Roche Acquires BioVeris II-56
Siemens Healthcare Diagnostics Inks Agreement with Amerinet II-56
Siemens Healthcare Diagnostics Signs Agreement with Bio-Rad II-56
Siemens Medical Solutions USA Sets Up Siemens Healthcare
Diagnostics II-56
Siemens Medical Solutions Acquires Diagnostic Products
Corporation II-57
Inverness Medical Innovations Acquires Immunoassay Business of
ACON Laboratories Inc II-57
Omni USA Acquires Brendan Technologies Inc II-57
China Medical Technologies Develops Two HIV Diagnostic Reagents II-57
Nanogen Acquires Immunoassay Test Business of Spectral
Diagnostics II-57
OXIS International Acquires BioCheck II-57
Beckman Coulter Acquires Diagnostic Systems Laboratories II-58
Magellan acquires TekCel II-58
Abbott and IHC Sign A Contract II-58
Abbott Partners with Axis-Shield II-58
Gen-Probe Enters into an Agreement with Qualigen II-58
Beckman Coulter Signs Multiple Agreements with Premier II-59
Bio-Rad Acquires MJ GeneWorks (US) II-59
Roche Acquires Igen II-59
Bio-Rad and Enzon Signs Marketing Agreement (US) II-59
Bayer HealthCare Enters into a Two-Year Agreement with
Community of Sant’Egidio (US) II-59
Roche Diagnostics Provides a Non-Exclusive License to
Diagnostic Products (US) II-59
IDS Enters into an Licensing Agreement with Beckman Coulter (UK) II-60
Gyros AB Signs a Licensing and Development Agreement with
Fujirebio (Japan) II-60
DPC Enters into a Distribution Agreement with Thermo Electron
(US) II-60
DPC and Premier Signs Laboratory Supply Agreement (US) II-60
Procyon to Develop PSP94 Serum-Based Immunoassay II-60
Roche Wins AmeriNet® Contract II-61
Beckman Enters into an Agreement with R&D Systems II-61
Beckman Coulter Enters into an Agreement with Bio-Rad (US) II-61
Roche Receives FDA Approval for Elecsys® II-61
Bio Rad’s Immuno Assay Link up with Beckman Coulter Jumpstarts
US Market Entry II-61
IVAX Acquires Sigma’s Enzyme Immunoassay Product Line II-62
FDA Clears Bayer Diagnostics’ Complexed PSA (cPSA) Assay II-62
Spectral Diagnostics Inc. Licenses Troponin I Technology to
Abbott Laboratories II-62
Dade Behring Obtains a Non-Exclusive License from Roche
Diagnostics (US) II-62
Ecstasy Test Receives Clearance II-63
Tosoh Medics Launches Tumor Marker for Breast Cancer II-63
Tosoh Medics Launches Short Time Estradiol and Progesterone II-63
FDA clears Quantitative Immunoassay Testing System of Qualigen II-63
AIA-600 II Cleared for Early Detection of Prostate Cancer II-63
12. Focus on Select Market Participants II-65
Abbott Laboratories (US) II-65
Beckman Coulter Inc. (US) II-65
bioMérieux (France) II-66
Bio-Rad Laboratories Inc. (US) II-66
Roche Diagnostics (US) II-67
Siemens Healthcare Diagnostics (US) II-67
Ortho-Clinical Diagnostics Inc (US) II-67
13. Global Market Perspective II-69
Table 9: World Recent Past, Current & Future Analysis for
Immunoassay Systems by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Latin American Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-69
Table 10: World Long Term Projections for Immunoassay Systems
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
and Latin American Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) II-70
Table 11: World 10-Year Perspective for Immunoassay Systems by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific and Latin American
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-71
Immunoassay Systems Market by Product Segment II-72
Table 12: World Recent Past, Current & Future Analysis for
Enzyme Immunoassay Systems by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Latin American Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-72
Table 13: World Long Term Projections for Enzyme Immunoassay
Systems by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific and Latin American Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-73
Table 14: World 10-Year Perspective for Enzyme Immunoassay
Systems by Geographic Region - Percentage Breakdown of Value
Sales for US, Canada, Japan, Europe, Asia-Pacific and Latin
American Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-74
Table 15: World Recent Past, Current & Future Analysis for
Fluorescence Immunoassay Systems by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Latin American Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-75
Table 16: World Long Term Projections for Fluorescence
Immunoassay Systems by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Latin American Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) II-76
Table 17: World 10-Year Perspective for Fluorescence
Immunoassay Systems by Geographic Region - Percentage
Breakdown of Value Sales for US, Canada, Japan, Europe,
Asia-Pacific and Latin American Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-77
Table 18: World Recent Past, Current & Future Analysis for
Chemiluminescence Immunoassay Systems by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific and Latin American
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-78
Table 19: World Long Term Projections for Chemiluminescence
Immunoassay Systems by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Latin American Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) II-79
Table 20: World 10-Year Perspective for Chemiluminescence
Immunoassay Systems by Geographic Region - Percentage
Breakdown of Value Sales for US, Canada, Japan, Europe,
Asia-Pacific and Latin American Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-80
Table 21: World Recent Past, Current & Future Analysis for
Radio Immunoassay Systems by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Latin American Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-81
Table 22: World Long Term Projections for Radio Immunoassay
Systems by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific and Latin American Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-82
Table 23: World 10-Year Perspective for Radio Immunoassay
Systems by Geographic Region - Percentage Breakdown of Value
Sales for US, Canada, Japan, Europe, Asia-Pacific and Latin
American Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-83
Table 24: World Recent Past, Current & Future Analysis for
Nephelometric Immunoassay Systems by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Latin American
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-84
Table 25: World Long Term Projections for Nephelometric
Immunoassay Systems by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Latin American Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) II-85
Table 26: World 10-Year Perspective for Nephelometric
Immunoassay Systems by Geographic Region - Percentage
Breakdown of Value Sales for US, Canada, Japan, Europe,
Asia-Pacific and Latin American Markets for Years2003, 2008 &
2012 (includes corresponding Graph/Chart) II-86
III. MARKET
1. The United States III-1
A.Market Analysis III-1
Market Overview III-1
Leading Players III-1
Table 27: Leading Players in the US Immunoassay Instruments
Market (2005, 2006 & 2007): Percentage Breakdown by Value
Sales for Abbott, Siemens Healthcare Diagnostics, Beckman
Coulter, Bayer, Dade Behring, Roche, Ortho Diagnostics,
Diagnostic Products Corporation and Others (includes
corresponding Graph/Chart) III-1
Table 28: Leading Players in the US Immunoassay Products
(BNP and NT-proBNP) Market (2005)- Percentage Breakdown by
Value Sales for Abbott, Bayer, Beckman Coulter, Roche, Dade
Behring, DPC and Others (includes corresponding
Graph/Chart) III-2
US Market for Clinical Laboratory Instruments III-2
Trends in the Marketplace III-2
Laboratory Consolidation and Automation on a Rise III-3
Product Launches III-3
Strategic Corporate Developments III-10
Focus on Select Players III-21
B.Market Analytics III-24
Table 29: US Recent Past, Current & Future Analysis for
Immunoassay Systems by Product Segment - Enzyme Immunoassay
Systems, Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) III-24
Table 30: US Long Term Projections for Immunoassay Systems
by Product Segment - Enzyme Immunoassay Systems,
Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-25
Table 31: US 10-Year Perspective for Immunoassay Systems by
Product Segment - Percentage Breakdown of Value Sales for
Enzyme Immunoassay Systems, Fluorescence Immunoassay
Systems, Chemiluminescence Immunoassay Systems, Radio
Immunoassay Systems, and Nephelometric Immunoassay Systems
Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-26
2. Canada III-27
A.Market Analysis III-27
Market Overview III-27
Strategic Corporate Development III-27
B.Market Analytics III-27
Table 32: Canadian Recent Past, Current & Future Analysis
for Immunoassay Systems by Product Segment - Enzyme
Immunoassay Systems, Fluorescence Immunoassay Systems,
Chemiluminescence Immunoassay Systems, Radio Immunoassay
Systems, and Nephelometric Immunoassay Systems Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-27
Table 33: Canadian Long Term Projections for Immunoassay
Systems by Product Segment - Enzyme Immunoassay Systems,
Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-28
Table 34: Canadian 10-Year Perspective for Immunoassay
Systems by Product Segment - Percentage Breakdown of Value
Sales for Enzyme Immunoassay Systems, Fluorescence
Immunoassay Systems, Chemiluminescence Immunoassay Systems,
Radio Immunoassay Systems, and Nephelometric Immunoassay
Systems Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-29
3. Japan III-30
A.Market Analysis III-30
Market Highlights III-30
Japanese Medical Instrument Market III-30
Product Launches III-30
Strategic Corporate Developments III-31
Focus on Key Players III-32
B.Market Analytics III-33
Table 35: Japanese Recent Past, Current & Future Analysis
for Immunoassay Systems by Product Segment - Enzyme
Immunoassay Systems, Fluorescence Immunoassay Systems,
Chemiluminescence Immunoassay Systems, Radio Immunoassay
Systems, and Nephelometric Immunoassay Systems Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-33
Table 36: Japanese Long Term Projections for Immunoassay
Systems by Product Segment - Enzyme Immunoassay Systems,
Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-34
Table 37: Japanese 10-Year Perspective for Immunoassay
Systems by Product Segment - Percentage Breakdown of Value
Sales for Enzyme Immunoassay Systems, Fluorescence
Immunoassay Systems, Chemiluminescence Immunoassay Systems,
Radio Immunoassay Systems, and Nephelometric Immunoassay
Systems Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-35
4. Europe III-36
A.Market Analysis III-36
Table 38: European IVD Market, 2006: Leading Players by
Market Share for Roche, Dade, Abbott, Beckman, Bayer,
bioMerieux , OCD and Others (includes corresponding
Graph/Chart) III-36
Immunodiagnostic Products Market III-36
Trends in Immunodiagnostic Market III-37
Outlook III-37
European Market for Immunoassay Systems III-37
Factors Influencing European on-Isotopic Immunoassay Systems
Market: (On a Scale of 1 to 10) III-38
Applications III-38
Decreasing Profitability III-38
Market Scenario III-38
B.Market Analytics III-39
Table 39: European Recent Past, Current & Future Analysis
for Immunoassay Systems by Geographic Region - France,
Germany, Italy, the UK and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-39
Table 40: European Long Term Projections for Immunoassay
Systems by Geographic Region - France, Germany, Italy, the
UK and Rest of Europe Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) III-40
Table 41: European Recent Past, Current & Future Analysis
for Immunoassay Systems by Product Segment - Enzyme
Immunoassay Systems, Fluorescence Immunoassay Systems,
Chemiluminescence Immunoassay Systems, Radio Immunoassay
Systems, and Nephelometric Immunoassay Systems Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-41
Table 42: European Long Term Projections for Immunoassay
Systems by Product Segment - Enzyme Immunoassay Systems,
Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-42
Table 43: European 10-Year Perspective for Immunoassay
Systems by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, the UK and Rest of Europe
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-43
Table 44: European 10-Year Perspective for Immunoassay
Systems by Product Segment - Percentage Breakdown of Value
Sales for Enzyme Immunoassay Systems, Fluorescence
Immunoassay Systems, Chemiluminescence Immunoassay Systems,
Radio Immunoassay Systems, and Nephelometric Immunoassay
Systems Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-43
4a. France III-44
A.Market Analysis III-44
Market Trends III-44
bioMérieux - A Key Player III-44
B.Market Analytics III-45
Table 45: French Recent Past, Current & Future Analysis for
Immunoassay Systems by Product Segment - Enzyme Immunoassay
Systems, Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) III-45
Table 46: French Long Term Projections for Immunoassay
Systems by Product Segment - Enzyme Immunoassay Systems,
Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-46
Table 47: French 10-Year Perspective for Immunoassay Systems
by Product Segment - Percentage Breakdown of Value Sales for
Enzyme Immunoassay Systems, Fluorescence Immunoassay
Systems, Chemiluminescence Immunoassay Systems, Radio
Immunoassay Systems, and Nephelometric Immunoassay Systems
Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-47
4b. Germany III-48
A.Market Analysis III-48
Market Trends III-48
Table 48: Penetration of In Vitro Diagnostics in Different
User Groups in Germany (2006E): Percentage Breakdown for
Hospitals, OTC/ Pharmacies, Private Laboratories and
General Practitioners, Non-human Medicine, Blood Banks,
Research Institutes, and Others (includes corresponding
Graph/Chart) III-48
Product Launches III-49
Strategic Corporate Developments: Historic III-50
B.Market Analytics III-50
Table 49: German Recent Past, Current & Future Analysis for
Immunoassay Systems by Product Segment - Enzyme Immunoassay
Systems, Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) III-50
Table 50: German Long Term Projections for Immunoassay
Systems by Product Segment - Enzyme Immunoassay Systems,
Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-51
Table 51: German 10-Year Perspective for Immunoassay Systems
by Product Segment - Percentage Breakdown of Value Sales for
Enzyme Immunoassay Systems, Fluorescence Immunoassay
Systems, Chemiluminescence Immunoassay Systems, Radio
Immunoassay Systems, and Nephelometric Immunoassay Systems
Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-52
4c. Italy III-53
Market Analysis III-53
Market Overview III-53
Table 52: Italian Recent Past, Current & Future Analysis for
Immunoassay Systems by Product Segment - Enzyme Immunoassay
Systems, Fluorescence Immunoassay Systems,
Chemiluminescence Immunoassay Systems, Radio Immunoassay
Systems, and Nephelometric Immunoassay Systems Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-53
Table 53: Italian Long Term Projections for Immunoassay
Systems by Product Segment - Enzyme Immunoassay Systems,
Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-54
Table 54: Italian 10-Year Perspective for Immunoassay
Systems by Product Segment - Percentage Breakdown of Value
Sales for Enzyme Immunoassay Systems, Fluorescence
Immunoassay Systems, Chemiluminescence Immunoassay Systems,
Radio Immunoassay Systems, and Nephelometric Immunoassay
Systems Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-55
4d. The United Kingdom III-56
A.Market Analysis III-56
Market Highlights III-56
Strategic Corporate Development III-56
IDS - A Key Player in the UK III-56
B.Market Analytics III-57
Table 55: UK Recent Past, Current & Future Analysis for
Immunoassay Systems by Product Segment - Enzyme Immunoassay
Systems, Fluorescence Immunoassay Systems,
Chemiluminescence Immunoassay Systems, Radio Immunoassay
Systems, and Nephelometric Immunoassay Systems Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-57
Table 56: UK Long Term Projections for Immunoassay Systems
by Product Segment - Enzyme Immunoassay Systems,
Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-58
Table 57: UK 10-Year Perspective for Immunoassay Systems by
Product Segment - Percentage Breakdown of Value Sales for
Enzyme Immunoassay Systems, Fluorescence Immunoassay
Systems, Chemiluminescence Immunoassay Systems, Radio
Immunoassay Systems, and Nephelometric Immunoassay Systems
Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-59
4e. Rest of Europe III-60
A.Market Analysis III-60
Market Trends III-60
B.Market Analytics III-60
Table 58: Rest of Europe Recent Past, Current & Future
Analysis for Immunoassay Systems by Product Segment - Enzyme
Immunoassay Systems, Fluorescence Immunoassay Systems,
Chemiluminescence Immunoassay Systems, Radio Immunoassay
Systems, and Nephelometric Immunoassay Systems Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-60
Table 59: Rest of Europe Long Term Projections for
Immunoassay Systems by Product Segment - Enzyme Immunoassay
Systems, Fluorescence Immunoassay Systems,
Chemiluminescence Immunoassay Systems, Radio Immunoassay
Systems, and Nephelometric Immunoassay Systems Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-61
Table 60: Rest of Europe 10-Year Perspective for Immunoassay
Systems by Product Segment - Percentage Breakdown of Value
Sales for Enzyme Immunoassay Systems, Fluorescence
Immunoassay Systems, Chemiluminescence Immunoassay Systems,
Radio Immunoassay Systems, and Nephelometric Immunoassay
Systems Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-62
5. Asia-Pacific III-63
A.Market Analysis III-63
Market Highlights III-63
Growing In-Vitro Diagnostics (IVD) Market Fuels the Demand
for Immunoassay Instruments in Asia III-63
Review of Select Asian Markets III-63
China III-63
Chinese Market for Diagnostic Products III-63
Influencing Forces III-64
Market Characteristics III-64
Competitive Analysis III-64
Strategies III-64
End-User Analysis III-65
Hospitals III-65
Laboratories III-65
General Population III-65
Difficulties Posed by the Market III-65
Distribution Channels III-66
Malaysia III-66
Health Care Services III-66
Singapore III-66
Clinical Laboratory Equipment Market in Singapore III-66
Market Characteristics III-67
Imports Scene III-67
Distribution III-67
End-User Analysis III-67
Strategic Corporate Development III-68
B.Market Analytics III-69
Table 61: Asia Pacific Recent Past, Current & Future
Analysis for Immunoassay Systems by Product Segment - Enzyme
Immunoassay Systems, Fluorescence Immunoassay Systems,
Chemiluminescence Immunoassay Systems, Radio Immunoassay
Systems, and Nephelometric Immunoassay Systems Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-69
Table 62: Asia Pacific Long Term Projections for Immunoassay
Systems by Product Segment - Enzyme Immunoassay Systems,
Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-70
Table 63: Asia Pacific 10-Year Perspective for Immunoassay
Systems by Product Segment - Percentage Breakdown of Value
Sales for Enzyme Immunoassay Systems, Fluorescence
Immunoassay Systems, Chemiluminescence Immunoassay Systems,
Radio Immunoassay Systems, and Nephelometric Immunoassay
Systems Markets for2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-71
6. Latin America III-72
Market Analysis III-72
Table 64: Latin American Recent Past, Current & Future
Analysis for Immunoassay Systems by Product Segment - Enzyme
Immunoassay Systems, Fluorescence Immunoassay Systems,
Chemiluminescence Immunoassay Systems, Radio Immunoassay
Systems, and Nephelometric Immunoassay Systems Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-72
Table 65: Latin America Long Term Projections for
Immunoassay Systems by Product Segment - Enzyme Immunoassay
Systems, Fluorescence Immunoassay Systems,
Chemiluminescence Immunoassay Systems, Radio Immunoassay
Systems, and Nephelometric Immunoassay Systems Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-73
Table 66: Latin American 10-Year Perspective for
Immunoassay Systems by Product Segment - Percentage
Breakdown of Value Sales for Enzyme Immunoassay Systems,
Fluorescence Immunoassay Systems, Chemiluminescence
Immunoassay Systems, Radio Immunoassay Systems, and
Nephelometric Immunoassay Systems Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-74
IV. COMPETITIVE LANDSCAPE
Get this report today!
Talk to Alison
00 1 718 618 48 97
Send Your Request
With the rapidly diversifying diagnostic industry, the In Vitro Diagnostic (IVD) has evolved as a major contributing segment. Extensive scientific research and development, technological advancements, ...
This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological warfare ...
In-Vitro Diagnostic (IVD) Market (Applications, End-users & Types) Trends & Global Forecasts (Major & Emerging Markets - G7, Japan & BRIC) (2011-2016) The global IVD market was valued at $44 billion in ...
... David kelso oak ridge april 20, 2012 in vitro diagnostic platforms for the developing world center for innovation in global health technologies industry academia philanthropy ...
... Cancer markers, cardiac markers, genetic tests all ivds not in a, c or d e.G. Vitamin b12, poc, urine test strips. Similar to general ivds no ivdd equivalent similar to annex ii list b similar ...
... Diagnostics In vivo imaging In vitro diagnostics drug delivery Nano pharmaceuticals 1 2 long term growth sectors in nanomedicine regenerative medicine Smart biomaterials Cell therapy Nanodevices 3 source ...
Canada
Europe
Japan
United States
World
Reportlinker.com © Copyright 2012. All rights reserved




